Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017

  • ID: 4413703
  • Clinical Trials
  • Region: Global
  • 63 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Celgene Corp
  • MORE
Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017

Summary

The clinical trial report, “Hidradenitis Suppurativa Global Clinical Trials Review, H2, 2017" provides an overview of Hidradenitis Suppurativa clinical trials scenario. This report provides top line data relating to the clinical trials on Hidradenitis Suppurativa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). The Clinical Trial Reports are generated using the author’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Reasons to buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • AbbVie Inc
  • Amgen Inc
  • AstraZeneca Plc
  • Bayer AG
  • Celgene Corp
  • MORE
  • Report Guidance
  • Clinical Trials Report Coverage
  • Clinical Trials by Region
  • Clinical Trials and Average Enrollment by Country
  • Top Countries Contributing to Clinical Trials in Asia-Pacific
  • Top Five Countries Contributing to Clinical Trials in Europe
  • Top Countries Contributing to Clinical Trials in North America
  • Top Countries Contributing to Clinical Trials in Middle East and Africa
  • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
  • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
  • Top Companies Participating in Hidradenitis Suppurativa Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Hidradenitis Suppurativa
  • Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa
  • Sep 07, 2017: InflaRx Reports Topline Phase IIa Clinical Results of IFX-1 for the Treatment of Hidradenitis Suppurativa
  • Clinical Trial Profile Snapshots
  • Appendix
  • Abbreviations
  • Definitions
  • Research Methodology
  • Secondary Research
  • About
  • Contact
  • Source
List of Tables
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Region, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Europe, Top Five Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, North America, Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Central and South America, Top Countries, 2017*
  • Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials, G7 Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials, E7 Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials In Progress by Phase 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hidradenitis Suppurativa Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
List of Figures
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Region (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, North America, Top Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2017*
  • Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials, G7 Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, G7 Countries, Clinical Trials by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017*
  • Proportion of Hidradenitis Suppurativa to Dermatology Clinical Trials, E7 Countries (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, E7 Countries, Clinical Trials by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Phase (%), 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials In Progress by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics, Global, Clinical Trials by Trial Status, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, by End Point Status, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016
  • Hidradenitis Suppurativa Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Key Sponsors, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017*
  • Hidradenitis Suppurativa Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017*
  • Methodology
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • AstraZeneca Plc
  • Amgen Inc
  • XBiotech Inc
  • Novartis AG
  • Innovation Pharmaceuticals Inc
  • Coherus BioSciences Inc
  • Celgene Corp
  • Bayer AG
  • Abbott Laboratories
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll